ReviewCurrent heart failure reports2026
Beyond Continuous-Flow: The Next Wave of Fully Implantable LVADs and Total Artificial Hearts.
Review in Current heart failure reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewVentricular assist devices (VADs) have evolved from a bridge-to-transplantation strategy into a cornerstone of long-term advanced heart failure management. While continuous-flow technology has dramatically improved survival and device reliability, the paradigm shift toward extended mechanical circulatory support has exposed critical unresolved challenges. This review examines current limitations and four transformative technological directions shaping the next generation of VAD therapy. RECENT
findingsFour key areas are driving innovation in the field. First, growing evidence linking prolonged non-pulsatile hemodynamics to vascular dysfunction and hemorrhagic complications has renewed interest in miniaturized pulsatile devices, with multiple engineering approaches under active investigation. Second, the development of physiologically responsive "smart pump" technology represents a major advance, enabling dynamic modulation of pump output in response to patient hemodynamic demands. Third, transcutaneous energy transfer (TET) systems combined with advanced battery technologies are progressing toward fully implantable designs that would eliminate driveline-related infections, a persistent and clinically significant complication of current-generation devices. Fourth, total artificial heart (TAH) development continues to advance, with both pulsatile and continuous-flow platforms incorporating TET technology to address biventricular failure. Despite ongoing challenges in balancing miniaturization, durability, and biocompatibility, these four innovations collectively hold promise for transforming mechanical circulatory support into a viable long-term therapeutic option, improving both survival and quality of life for a broader population of patients with advanced heart failure.
Indexed as
Identifiers
42126476What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.